Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update

Aura Biosciences, Inc. (NASDAQ:AURA) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 2,450,000 shares, an increase of 9.4% from the March 15th total of 2,240,000 shares. Based on an average daily trading volume, of 179,700 shares, the days-to-cover ratio is presently 13.6 days. Approximately 6.2% of the shares of the company are sold short.

Insiders Place Their Bets

In other Aura Biosciences news, CFO Julie B. Feder sold 6,609 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $7.64, for a total transaction of $50,492.76. Following the transaction, the chief financial officer now owns 62,991 shares of the company’s stock, valued at $481,251.24. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CFO Julie B. Feder sold 6,609 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $7.64, for a total value of $50,492.76. Following the transaction, the chief financial officer now owns 62,991 shares of the company’s stock, valued at $481,251.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Los Pinos Elisabet De sold 15,853 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $7.64, for a total value of $121,116.92. Following the completion of the transaction, the insider now directly owns 161,438 shares in the company, valued at approximately $1,233,386.32. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in AURA. Eventide Asset Management LLC lifted its stake in Aura Biosciences by 91.8% during the fourth quarter. Eventide Asset Management LLC now owns 5,802,682 shares of the company’s stock worth $51,412,000 after purchasing an additional 2,777,777 shares during the last quarter. Matrix Capital Management Company LP raised its position in Aura Biosciences by 29.1% during the 4th quarter. Matrix Capital Management Company LP now owns 6,922,870 shares of the company’s stock worth $61,337,000 after purchasing an additional 1,560,000 shares during the last quarter. Decheng Capital Management III Cayman LLC raised its position in Aura Biosciences by 296.5% during the 3rd quarter. Decheng Capital Management III Cayman LLC now owns 1,163,123 shares of the company’s stock worth $10,433,000 after purchasing an additional 869,790 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in Aura Biosciences during the 4th quarter worth $7,762,000. Finally, Goldman Sachs Group Inc. raised its position in Aura Biosciences by 255.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,026,904 shares of the company’s stock worth $12,682,000 after purchasing an additional 738,406 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Trading Down 3.0 %

NASDAQ:AURA traded down $0.23 during trading hours on Tuesday, reaching $7.32. 65,599 shares of the company were exchanged, compared to its average volume of 172,605. Aura Biosciences has a 1-year low of $5.99 and a 1-year high of $13.50. The business has a 50 day moving average of $8.17 and a 200 day moving average of $8.32.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.